Introduction and Rationale
Wound care is a major clinical challenge and presents an enormous burden to health care worldwide [1] [2] [3] . As wounds (chronic and acute) heal, a number of key biological changes occur at the wound site at the tissue and cellular level [2] . Among these are inflammation, reformation of the epidermal barrier, and remodeling of the connective tissue in the dermis.
However, a common major complication arising during the wound healing process, which can range from days to months, is bacterial infection [2, 3] . This can result in a serious impediment to the healing process and lead to significant complications, especially in chronic non-healing wounds. Currently, the standard wound care includes monitoring for possible infection by direct visual inspection under white light and by taking samples for analysis in the laboratory which takes approximately two days to provide a result. However, qualitative visual assessment only provides a gross view of the wound site (i.e., presence of purulent material and crusting) but does not provide the critically important information about underlying changes that are occurring at the tissue and cellular level (i.e., infection, matrix remodeling, inflammation, and necrosis).
All chronic wounds contain bacteria, but identifying whether the wound is in bacterial balance (e.g. contamination with organisms on the surface or colonization with organisms in the tissue arranged in micro colonies without causing damage) or bacterial imbalance (e.g. critical colonization and infection) is of primary clinical importance as it is a major determinant of the rate of healing. Also, it is important to note that there is a continuum of bacterial presence progressing from bacterial balance to imbalance leading to bacteria-mediated tissue damage in a chronic wound. These bacteria include common species typically found at wound sites (i.e., Staphylococcus and Pseudomonas species) [1, 2, 10, 11] . The diagnosis of infection is typically made clinically, based on standard signs and symptoms [3] identified during examination in and around the local wound bed, the deeper structures, and the surrounding skin by the wound care team. However, a major problem in conventional practice is that bacteria within and around a wound cannot be directly visualized with the unaided eye under standrad room lighting with white light. Diagnosis is typically informed by clinical signs and symptoms of infection based on the symptoms caused by bacterial contamination and/or infection within the wound (i.e., pain, purulent exudate, crusting, swelling, erythema, heat) [2] [3] [4] . On suspicion of infection, the wound care team will often sample the wound using either surface swabbing or biopsy for clinical microbiological testing.
Bacterial swabs are collected at the time of wound examination and have the advantage of providing identification of specific bacterial/microbial species and quantification of bacterial burden. However, often, multiple swabs are collected randomly from the wound site and these are not targeted, and some swabbing techniques may spread the microorganisms around with the wound during the collection process, thus affecting patient healing time and morbidity. This may be a problem especially with large chronic (non-healing) wounds where the detection yield for bacterial presence is suboptimal, despite the collection of multiple swabs [15] . Furthermore, bacteriological culture results often take about 2-4 days to come back from the laboratory, thus significantly delaying diagnosis and treatment [15] . Thus, bacterial swabs do not provide realtime detection of infectious status of wounds. In addition, although wound swabbing appears to be straightforward, it can lead to inappropriate treatment, patient morbidity and increased hospital stays if not performed correctly. Therefore, an image-based method that allows realtime monitoring of wound healing, particularly early dermal connective tissue remodeling, and the presence of bacterial contamination and/or infection over time could have a significant clinical impact.
Another aspect of bacterial impact on wound healing relates to connective tissue breakdown. The remodeling and healing of connective tissues in wounds involves simultaneous synthesis and degradation of collagen fibrils [8, 9] . This degradation process is driven by bacterial imbalance with the host which leads to increased enzymatic-breakdown by proteases released by the bacteria. Autofluorescence imaging provides a powerful means of visualizing both bacteria and connective tissue in real-time. Autofluorescence has been used previously (by our own team) in other clinical applications, for example, in gastroenterology to image both collagen and bacterial fluorescence in clinical studies [5] [6] [7] . Thus, we wish to expand the use of tissue autofuorescence imaging technology to wound care and management in order to obtain biologically relevant information about the wound site at the tissue and biomolecular levels in real-time during the healing process [5] [6] [7] . When used to assess wounds, tissue autofluorescence may aid in determining the degree of wound healing (e.g. by visualizing and measuring connective tissues) and the presence of bacterial infection.
In preliminary preclinical testing, we have discovered that when wounds are illuminated by violet/blue light, endogenous collagen in the connective tissue matrix emit a characteristic green fluorescent signal [6] , while most pathogenic bacterial species emit a unique red fluorescence signal due to the production of endogenous porphyrins [5] . Therefore, with autofluorescence imaging, no exogenous contrast agents are needed during imaging, making this approach particularly appealing as a diagnostic imaging method for clinical use.
We have recently developed an innovative optical molecular imaging platform (called PRODIGI™) based on high-resolution fluorescence and white-light technologies in a hand-held, real-time, high-resolution, non-invasive format. PRODIGI™ offers a non-contact means of obtaining instantaneous image-based measurements of diagnostically-relevant biological and molecular information of a wound and surrounding skin tissues for the first time and could have significant impact on improving conventional wound care, management, and guidance of compared with changes in wound size over time.
2)
To determine the effectiveness of the fluorescence imaging device in detecting the presence (or contamination) of bacteria in and around a wound (including infection), compared with standard best practice methods using white light visualization and clinical signs and symptoms, with swabbing and bacteriology as the 'gold standard'.
3)
To identify the relationships between autofluorescence imaging of collagen and bacteria in wounds (including the wound margin) and the following: i) clinical signs of infection, ii) microbial load (i.e., number of organisms per gram of wound tissue), and iii) diversity of microbial species in the wound (i.e., number of different species isolated per wound), and Gram signing.
4)
To assess the potential utility of the device to guide intervention and alter the course of treatment in wounds that are infected.
Overall Study Design

Hypothesis
We hypothesize that real-time imaging of tissue autofluorescence signals emanating from endogenous connective tissue (e.g. collagen) and pathogenic bacteria within complex wounds can be used to determine healing status (i.e., collagen re-modeling and wound closure), detect wound bacterial contamination and/or infection that is occult under standard clinical white light evaluation, and guide intervention during wound care. A translator will be provided to patients who are unable or uncomfortable communicating in English.
Clinical Setting and Patient Enrollment Criteria
Specific Study Procedures Standard White Light-Based Clinical Wound Assessment
Patients who meet the entry criteria (determined by staff at the JDRTC) with chronic wound problems will be informed and consent will be obtained to participate in this trial by the UHN research staff (Consent Form and Study Instrument Document are attached). In our experience, the majority of patients at the JDRTC have presented with diabetic-related chronic wounds in the lower extremities and so we expect to enroll a majority of the study patients with foot ulcers. Such patients are typically enrolled for treatment at the JDRTC and wait about 2 -3 weeks prior to receiving treatment (herein called intervention) such as hyperbaric oxygen treatment, antibiotics, debridement, ultrasound therapy, etc. Throughout their enrollment at the JDRTC, patients will have their wounds prepared by standard methods, and will be assessed for standard clinical signs and symptoms (CSS) of localized infection in their wounds by the attending clinician or trained wound care specialist, according to standard clinical practice employed at the treatment site. Clinical staff will take the patient's medical history, including age and gender. Demographic data (e.g. diabetes) will be collected from the patient record (patient identification will be maintained using a unique subject/patient identification number Data regarding the type, location, and history of the study wound will be collected from direct observation, the patient record and patient/caregiver report by the clinical team. In order to measure wound depth, a cotton-tipped swab will be placed in the deepest area of the wound and marked at the point level with the surrounding peri-wound skin. For chronic diabetic wounds the type and amount of wound bed tissue will be measured using the necrotic tissue subscale of the Pressure Sore Status Tool (PSST) [12] . Necrotic tissue will be defined as yellow, tan, brown, gray or black tissue in the wound bed after cleansing the surface of the wound bed with saline-moistened gauze, which ensured the necrotic tissue will be adherent [13] . The category descriptors on the 5-point scale were: 1 = none present; 2 = <25-percent wound bed covered; 3 = 25-to 50-percent wound bed covered; 4 = >50 and <75-percent wound bed covered; and 5 = 75-to 100-percent wound bed covered.
Surface area and depth will serve as measures of wound size. Surface area will be measured by tracing the wound edge on the white light image of the wound (and labeled with patient ID, date and wound ID) using an indelible marker with a 1 mm tip. The wound edge will be defined as the line dividing the healed portion from the unhealed portion of the wound. The depth of the wound will be measured using a cotton-tipped swab placed in the deepest portion of the wound. The amount of necrotic tissue in the wound bed will be rated using direct observation, and the PSST. The presence or absence of the clinical signs and symptoms of infection will be assessed using the Clinical Signs and Symptoms Checklist (CSSC) [14] and each wound will be categorized as infected or non-infected by the researcher based on the For subjects with more than one eligible chronic wound (i.e., full-thickness and nonarterial), one wound will be randomly selected (i.e., random draw) for data collection procedures. If other 'eligible wounds' are available for a single patient, imaging of this wound will be conducted at the discretion of the physician and based on the time available to the clinical team for the additional procedure. All study data will be collected by a member of the research team and will be recorded on a Case Report Form labeled with subject/patient identification number only, which will be kept in secure storage (double locked) location during the study at the JDRTC.
After the initial data is collected for each wound, a high-resolution white light photograph (using a length scale placed in the field of view to aid in wound size measurements) will be taken of each wound using the imaging device and printed on a color printer, immediately after the wound has been examined. The clinician (or wound care personnel) will be asked to draw (using an indelible ink pen) on the photograph to indicate the area he/she considers infected with bacteria and thus would normally take a bacterial swab or biopsy (each photo will be labeled with patient ID, date and wound ID). However, no swabs or biopsies will be taken at this time. Immediately after the physician has 'committed' to their decision of bacterial infection on the wound and areas that would require swabbing for microbiology confirmation at diagnosis, PRODIGI™ will subsequently be used to take fluorescence images of the wounds. We will perform fluorescence imaging of selected wound sites in each patient following standard white light-based clinical assessment using the prototype device. Fluorescence imaging with the device and point-spectroscopy measurements will be performed on the selected wound from a patient's limb as well as a non-wounded contralateral limb (as a control) from a single patient.
Fluorescence imaging and spectroscopy measurements
The PRODIGI™ device used here allows non-contact and non-invasive imaging of the wound surface, and images are collected in approximately 1-2 seconds using both white light images into its digital memory card for analysis afterwards. If bacteria are detected on the second pass (using the fluorescence imaging device and spectroscopy measurements where appropriate) which are undetected during the standard clinical wound assessment procedure (first pass), then bacterial swabbing and/or tissue biopsy will be obtained from these bacteriared and bacteria-green fluorescence positive areas and sent for bacteriology testing to a blinded microbiology lab. Conversely, if bacteria are not detected on the second pass using fluorescence imaging but were detected during the standard clinical wound assessment procedure (first pass), then bacterial swabbing and/or tissue biopsy will be obtained from these areas and also sent for bacteriology testing to a blinded microbiology lab.
Multiple point fluorescence spectroscopy measurements will be made, at the discretion of the research team, to determine specific autofluorescence spectral signatures of unique fluorescence features observed during imaging. This will be within and around the wound using a custom-built laptop computer-controlled portable 'spectroscopy' device (See Fig. 2 , Study Instruments). If deemed appropriate, areas of the wound bed and edge will be measured using the spectroscopy probe. Fluorescence imaging and spectroscopy measurements require that the room lights be dimmed or turned off during the examination for a brief time, to minimize the background light.
This device uses an optical fiber probe, which is held close to the wound surface (but not in contact) to collect the fluorescence signal from the wound and sends this information to the spectrometer which separates the light signal into different colors (wavelengths), and this data is stored on the laptop computer. Tissue spectra will be collected using the same blue light LED (405 nm emission) of the fluorescence imaging device. This measurement will be made after the fluorescence digital imaging is completed for each wound, and is estimated to take about 1-2 minutes. Spectra will be collected from areas of interest as determined by the fluorescence imaging device. Any areas that appear abnormal under fluorescence (e.g. suspected application of a topical skin cream, lotion, etc.) will also be measured to create a database of and spectroscopy data obtained from these wound measurements will be stored on an encrypted laptop computer for subsequent analysis, which will be stored in a secure (doublelocked) location at the JDRTC.
Swabbing and Bacteriology
A swab or biopsy will be collected from each area marked as being suspicious for infection in the printed color photos of both the white light and autofluorescence images taken with the prototype device. The swab/biopsy will be done in an area which has consensus from at least two study staff in order to determine the bacterial burden in each marked area. The study staff will indicate consensus by both initialing the fluorescence image after the areas have been marked.
For each marked area (e.g. from the white light and fluorescence color photos), a bacterial swab or a specimen of viable wound tissue will be removed aseptically using a standard sterile swab or a dermal punch instrument, and this will be determined by the wound care specialist/physician. The tissue specimen will be placed in sterile container and transported to the microbiology laboratory for processing by the end of the day. These will be used for gram signing of the bacteria. All organisms isolated will be identified using standard microbiologic procedures, which are based on criteria such as colony morphology and gram stain appearance [15] .
Therefore, for each patient in this study, a complete data file will include (for each visit to the clinic): white light visualization and clinical signs and symptoms of each wound examined (performed by the clinician), white light and corresponding autofluorescence images of the wound obtained using the prototype device, corresponding fluorescence spectra (performed by research staff when appropriate) and bacteriology results obtained from swabbing/biopsy (performed at bacteriology lab). These data will be collated into and stored in a global database for the duration of the study and this will be stored on an encrypted computer in a secure location at the JDRTC.
Question Based Survey
A semi-structured survey will be administered that combines both numeric and qualitative comment boxes, to assess the informational needs of the target population. The questions will be closed-ended to provide discrete numerical or nominal data points. The patient survey will generally include two broad sections:
1. Demographic data of the patients. These will specifically include age, level of education, and annual household income. about the PRODIGI™ technology before it is used in their care will be elucidated, along with the medium through which they would like that information communicated. These informational needs will be compared with the patient's socioeconomic status to assess if there is in fact a difference in informational needs with differing socioeconomic status.
Handling of Research Equipment During Study
The prototype fluorescence imaging device and the spectroscopic optical fiber probe will not come in contact with patients during imaging and spectroscopy measurements. However, to further increase sterility of all research equipment between patients and over time, after each imaging and spectroscope session, all equipment surfaces (e.g. prototype device, printer, computer) will be wiped clean using 70% ethyl alcohol. To date, we have not had any safety or contamination issues with the PRODIGI™ device in parallel clinical testing.
Longitudinal Imaging of Each Patient
Patients enrolled in this study will be followed over a period of time since wound assessment is performed over several visits, lasting weeks to months. Patients visit the JDRTC for pre-intervention "work-up" and post-intervention follow up care according to a predetermined schedule determined by their clinician and wound care team. Therefore, this study will involve multiple longitudinal time-point autofluorescence imaging sessions for each patient, allowing us to quantitatively track changes in the PSST, SCCS, or BWAT over time. We recognize that many wounds may not close prior to the end of the study therefore, we will measure and track the changes in wound size (and depth) during all visits for a patient until the end of this study.
Furthermore, the number of pre-intervention "work-up" and post-intervention follow up visits may vary due to variability in wound etiologies, unpredictable efficacy of the treatment, and logistical difficulties in scheduling. The research staff will accommodate the fluctuations in scheduling as much as reasonably possible, however it is understood that the longitudinal assessment of the wounds may in some cases be inconsistent with respect to the number of follow-up visits. We do not anticipate that an inconsistent number of follow up visits will compromise the integrity of the data collected or its analyses/interpretation within the scope and goal of this study.
All imaging and spectral data obtained will be stored with a unique patient identification number which will facilitate consistent tracking of patients over several clinical visits. Table 1 shows an example of the various procedures that will be performed during each patient visit over the course of the study. 
Data Collection
All study data (demographics, images, survey) will be collected by a member of the research team and will be recorded on a Case Report Form labeled with subject identification number. Demographic data will be collected from the patient record. For subjects with more than one eligible chronic wound, one wound will be randomly selected (i.e., random draw) for data collection procedures. Data regarding the type, location, and history of the study wound will be collected from direct observation, the patient record and patient/caregiver report. Data collected during this study may be used to affect patient care. The clinical staff will determine the appropriate intervention, understanding and considering the utility and limitations of the fluorescence image. The intervention will be documented by the research team.
Intervention
The 
Adverse events
There are no known or perceived risks to the patient associated with this study as A major aim of this trial using the prototype PRODIGI TM fluorescence device is to gather important qualitative information about its general utility within the clinical wound care environment. For example, we are interested in learning from clinicians and other wound care
personnel about the ease of use of the device and how it will be best used in the conventional clinical setting. In addition, we wish to determine the value of various existing features and capabilities as well as potential additional features required in subsequent versions of the device. In addition to this qualitative evaluation, we will also conduct quantitative analyses of all imaged and measured data obtained during this study, using established statistical methods.
The ability of the prototype PRODIGI™ fluorescence device to image wound remodeling (i.e., changes in collagen concentration and biodistribution) during wound healing will be determined by correlating the increase in green (collagen) autofluorescence intensity and biodistribution within the wound bed and at the wound boundary with measurements of the wound size (e.g. white light grid-based tracing measurements), over the course of the patient's involvement in the study. This information will help to determine if the prototype device can provide information about wound re-modeling in real-time that is indicative of wound healing (i.e., decrease in wound size and thus wound closure). Furthermore, the green fluorescence channel in the images obtained using the device will provide information about the wound margin (e.g. circumference).
Study wounds will be grouped according to whether or not bacteria were isolated and identified during microbiological laboratory procedures. Those containing any amount of bacteria (regardless of species) will be categorized as bacteria-positive wounds (e.g. contaminated). Those that were negative for bacteria will be categorized as bacteria-negative wounds. The bacteria-positive and bacterial-negative wounds will be examined for differences in clinical signs of infection using Fisher's exact tests. Differences between the bacteria-positive and bacterial-negative groups with respect to microbial load and diversity of species will be statistically examined using t-tests for independent groups. An alpha level of 0.05 (two-tailed) will be employed. Sensitivity and specificity for detecting bacteria in wounds will be calculated both per-wound and per-patient (a measure of ability to detect and correctly diagnose bacterial contamination in the wound). Furthermore, statistical analysis of multiple variables will be used to determine sensitivity, specificity and predictive value of the fluorescence imaging device for detecting (white light-occult) bacterial infection in wounds compared with standard methods.
Bacteriology results will be pooled for each wound type across the total patient population and scored based on CFU data in order to determine the percentage of wounds that were contaminated, colonized, critically colonized and infected. Statistical analysis will be used to determined degree of correlation between fluorescence intensity and the level of bacterial presence progressing from bacterial balance to bacterial damage in each chronic wound type.
This data will be used to determine whether fluorescence imaging can differentiate whether a given wound type is in bacterial balance (contamination with organisms on the surface or colonization with organisms in the tissue arranged in micro colonies without causing damage) or bacterial imbalance (critical colonization and infection), which is of primary importance to healing.
Potential Impact
We believe that this study will aid in developing an important new imaging tool for real- With an aging population, the number of people at risk for chronic ulcers is expected to increase, thus the need for advanced wound care will increase.
Our study aims to develop PRODIGI™ as a new medical device to directly impact patient care by allowing cost-effective monitoring of chronic and acute wounds in real-time for
